These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1480 related articles for article (PubMed ID: 24373150)

  • 1. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
    Seufert J; Gallwitz B
    Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Pinelli NR; Hurren KM
    Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GLP-1 receptor agonists: effects on cardiovascular risk reduction.
    Lorber D
    Cardiovasc Ther; 2013 Aug; 31(4):238-49. PubMed ID: 23865382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?
    Peterson G
    Ann Med; 2012 Jun; 44(4):338-49. PubMed ID: 22530845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.
    Christensen M; Miossec P; Larsen BD; Werner U; Knop FK
    Expert Opin Drug Discov; 2014 Oct; 9(10):1223-51. PubMed ID: 25119443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular safety and benefits of GLP-1 receptor agonists.
    Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
    Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
    Iepsen EW; Torekov SS; Holst JJ
    Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GLP-1 receptor agonists: a clinical perspective on cardiovascular effects.
    Mundil D; Cameron-Vendrig A; Husain M
    Diab Vasc Dis Res; 2012 Apr; 9(2):95-108. PubMed ID: 22496442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
    Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
    Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits.
    Ryder RE
    Diabet Med; 2013 Oct; 30(10):1148-55. PubMed ID: 24073725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association.
    Cariou B
    Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S28-6S35. PubMed ID: 26774017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
    Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
    BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.
    Monami M; Marchionni N; Mannucci E
    Eur J Endocrinol; 2009 Jun; 160(6):909-17. PubMed ID: 19318378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results.
    Madsbad S
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):463-77. PubMed ID: 19748064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging GLP-1 receptor agonists.
    Lund A; Knop FK; Vilsbøll T
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):607-18. PubMed ID: 21905764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
    van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
    Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials.
    Monami M; Dicembrini I; Nardini C; Fiordelli I; Mannucci E
    Diabetes Res Clin Pract; 2014 Feb; 103(2):269-75. PubMed ID: 24485345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 74.